According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies.
Read the full article here:
In 2022, IFPA and IPC announced a new partnership to join their clinical expertise and the patient perspective. Here’s what they hope to achieve together.
Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
